ADC Therapeutics (ADCT) EBT (2020 - 2026)
ADC Therapeutics (ADCT) posted EBT of -$33.0 million for Q1 2026, up 19.52% sequentially from -$41.0 million in Q3 2025, and up 14.23% YoY from -$28.9 million in Q1 2025.
ADC Therapeutics (ADCT) EBT (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported EBT for 7 years, with the latest figure at -$33.0 million in Q1 2026.
- Quarterly EBT rose 14.23% year-over-year to -$33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$167.8 million (down 2.56% YoY) and the FY2022 annual result came in at -$152.6 million, up 33.84% from the prior year.
- EBT climbed to -$33.0 million in Q1 2026 per ADCT's latest filing, from -$41.0 million in the prior quarter.
- Over five years, EBT peaked at -$17.8 million in Q1 2022 and troughed at -$65.3 million in Q2 2022.
- A 5-year average of -$43.1 million and a median of -$44.5 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2023: EBT soared 65.32% in 2022, then sank 234.74% in 2023.
- Over 5 years, EBT stood at -$18.2 million in 2022, then slumped by 150.11% to -$45.4 million in 2023, then gained by 3.93% to -$43.6 million in 2024, then increased by 6.08% to -$41.0 million in 2025, then rose by 19.52% to -$33.0 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$33.0 million, -$41.0 million, and -$55.4 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | -16.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.57 Mn |
| Mar 31, 2026 | -32.97 Mn |
| Sep 30, 2025 | -40.97 Mn |
| Jun 30, 2025 | -55.39 Mn |
| Mar 31, 2025 | -38.44 Mn |
| Sep 30, 2024 | -43.62 Mn |
| Jun 30, 2024 | -35.71 Mn |
| Mar 31, 2024 | -45.80 Mn |
| Sep 30, 2023 | -45.40 Mn |
| Jun 30, 2023 | -52.70 Mn |
| Mar 31, 2023 | -59.69 Mn |
| Dec 31, 2022 | -18.15 Mn |
| Sep 30, 2022 | -51.32 Mn |
| Jun 30, 2022 | -65.32 Mn |
| Mar 31, 2022 | -17.83 Mn |
| Dec 31, 2021 | -35.52 Mn |
| Sep 30, 2021 | -71.40 Mn |
| Jun 30, 2021 | -72.33 Mn |
| Mar 31, 2021 | -51.42 Mn |
| Dec 31, 2020 | -56.26 Mn |